CKD
Aug 30, 2022
Aktis’s Novel Targeted Alpha Radiopharmaceuticals; Koye Partners with Sonde Health; Novartis to Spin Off Sandoz Business; Alcon to Buy Aerie Pharma; Fast Track Designation to Merck’s MK-2060; FDA Approves Ibrutinib for Chronic GvHD; French Authorities Clears BrainVectis’s Clinical Trial; Takeda’s Dengue Vaccine TAK-003 Gets Approval in Indonesia
Aktis Oncology Raises USD 84 Million To Advance Novel Targeted Alpha Radiopharmaceuticals Aktis Oncology has raised an additional USD 84 million in its Series A round, adding to the USD 72 million raised last year to help bring its radiopharmaceuticals to market. The extension to the first round included Merck's...
Read More...
Feb 10, 2017
Chronic Kidney Disease: Complex Debilitating Condition
Chronic Kidney Disease (CKD) is a major global public health problem which progresses slowly and get worse over time. It is the 8th leading cause of death in United States, and is characterized by kidney damage and reduced kidney function. According to National Kidney Foundation, approximately 26 millions of adults ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
